Emily Martin
Psychiatric/Mental Health · Birmingham, ALNPI 1184183923
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 350 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 22 manufacturers, the largest accounting for just 18.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $2,572 and has fallen 74.4% since, to $657 in 2025. Among psychiatric/mental health clinicians in AL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 350 payments — averaging $20.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- Johnson & Johnson$793
- Otsuka America Pharmaceutical, Inc.$672
- Takeda Pharmaceuticals U.S.A., Inc.$636
- Alkermes, Inc.$502
- Vanda Pharmaceuticals Inc.$441
- plus $3K from 16 others
What the payments were for
- Food & beverage$7,111100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 53 | $1,346 |
| Johnson & Johnson | 36 | $793 |
| Otsuka America Pharmaceutical, Inc. | 36 | $672 |
| Takeda Pharmaceuticals U.S.A., Inc. | 33 | $636 |
| Alkermes, Inc. | 28 | $502 |
| Vanda Pharmaceuticals Inc. | 19 | $441 |
| Teva Pharmaceuticals USA, Inc. | 30 | $436 |
| Lundbeck LLC | 21 | $416 |
| Corium, LLC | 15 | $368 |
| AbbVie | 23 | $346 |
| Neurocrine Biosciences, Inc. | 12 | $252 |
| Bausch Health US, LLC | 14 | $249 |
| Neos Therapeutics, LP | 4 | $172 |
| Supernus Pharmaceuticals, Inc. | 9 | $147 |
| Almatica Pharma LLC | 6 | $125 |
| Tris Pharma Inc | 3 | $58 |
| Axsome Therapeutics, Inc. | 2 | $37 |
| Merck | 2 | $33 |
| E.r. Squibb & Sons, L.L.C. | 1 | $24 |
| Sage Therapeutics, LLC | 1 | $22 |
| Noven Therapeutics, LLC | 1 | $19 |
| Ironshore Pharmaceuticals Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CAPLYTA$359
- Adzenys XR-ODT$118
How this compares
$7,111 in reported general payments places this provider in the 90th percentile of 378 psychiatric/mental health providers in Alabama.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lurasidone Hcl | 11 | $2,108 |
| Benztropine Mesylate | 14 | $244 |
| Duloxetine Hcl | 17 | $204 |
| Divalproex Sodium | 14 | $151 |
| Trazodone Hcl | 13 | $74 |
| Fluoxetine Hcl | 14 | $55 |
| Lamotrigine | 11 | $41 |
Paid to pharmacies, not to this prescriber.
Other psychiatric/mental health in Birmingham
- Yuliya SpencerBirmingham$65K
- David CoffmanBirmingham$13K
- Tiffany WallerBirmingham$12K
- Kellie VaughnBirmingham$12K
- Amanda BoydBirmingham$10K
- Hannah KeslerBirmingham$9K
- Judy ClarkBirmingham$9K
- Jessica AdwellBirmingham$9K
- Pamela Kite TrullBirmingham$9K
- Lacey PodyBirmingham$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.